Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 106M | 24M | 27M | 10M | 29M |
| Gross Profit | 90M | 16M | 25M | 10M | 27M |
| Operating Income | -4M | -87M | -50M | -43M | 8M |
| EBITDA | 99M | -76M | -44M | -26M | -8M |
| Net Income | 83M | -106M | -46M | -27M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$12.90
+2.30% today
1Y Change
+40.56%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zevra Therapeutics, Inc. (ZVRA) is a Healthcare stock with a market cap of $590.00M and listed on NASDAQ. The stock last traded around $12.90 and up 40.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +350.9%, EPS growth of +161.4%, a dividend yield of 0.0%. What stands out right now is revenue +350.9%, EPS +161.4%, free cash flow +96.5% with operating margin -59.1% and ROIC -24.6%. Valuation is more restrained than many high-expectation growth names at P/E 6.7 and price/sales 5.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZVRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZVRA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZVRA Max Drawdown
-43.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZVRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$28.7M
+182.0% YoY
FY Net Income
-$8.6M
+68.0% YoY
Free Cash Flow
$10.3M
+155.0% YoY
Revenue Growth
+350.9%
EPS Growth
+161.4%
Gross Margin
84.2%
Net Margin
78.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 106M | 24M | 27M | 10M | 29M |
| Gross Profit | 90M | 16M | 25M | 10M | 27M |
| Operating Income | -4M | -87M | -50M | -43M | 8M |
| EBITDA | 99M | -76M | -44M | -26M | -8M |
| Net Income | 83M | -106M | -46M | -27M | -9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62M | 34M | 43M | 65M | 112M |
| Total Assets | 285M | 178M | 172M | 115M | 133M |
| Total Liabilities | 130M | 138M | 110M | 40M | 6M |
| Shareholder Equity | 155M | 40M | 62M | 75M | 127M |
| Total Debt | 63M | 60M | 44M | 19M | 2M |
| Net Debt | 800K | 27M | 716K | -47M | -111M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+155.8% YoY
Capital Expenditures
102K
-9.7% YoY
Free Cash Flow
10M
+155.0% YoY
Key ratios
Gross Margin
84.2%
Operating Margin
-59.1%
Net Margin
78.2%
ROE
74.6%
Debt / Equity
0.41x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.